Key result
Correction notice addresses a title typo regarding incretin agonists for first-line antihypertensive therapy.
Answers are grounded in this paper and cite their sources.
Title typo correction leaves content unchanged; leaves open validation of incretin agonists as first-line antihypertensives.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kylies et al. (2026) studied Hypertension. Incretin Agonist-Based Drugs was evaluated. This is a correction notice for a typo in the title of the original article regarding incretin agonist-based drugs for first-line antihypertensive therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: